HRC0202 vs Trovocabtagene autoleucel (C-CAR088)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

HRC0202

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple MyelomaCAR-T (autologous, BCMA-directed)
Weak signal

NCT04003168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published report covers seven treated patients, fewer than the study's listed enrollment.

Reported efficacy

Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).

Result source: NCT04003168

Trovocabtagene autoleucel (C-CAR088)

Developed by AbelZeta Pharma, Inc.

Phase 1/2 in Multiple MyelomaCAR-T cell therapy
Weak signal

NCT03751293 · Phase 1 · status unknown

This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRC0202Trovocabtagene autoleucel (C-CAR088)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

HRC0202
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

OS, median

HRC0202
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

ORR

HRC0202
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

VGPR or better

HRC0202
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported

MRD negativity

HRC0202
—Not reported
Trovocabtagene autoleucel (C-CAR088)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRC0202: no structured comparison results are available for Multiple Myeloma.

Trovocabtagene autoleucel (C-CAR088): no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRC0202's landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape